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b Institut Catalá d’Oncologia (ICO), L’Hospitalet de Llobregat, Spain
c GEICAM Spanish Breast Cancer Group, Madrid, Spain
d Hospital Universitario Virgen del Rocı́o, Sevilla, Spain
e Hospital Universitario 12 de Octubre, Madrid, Spain
f HM Hospitales Madrid, Spain
g SOLTI Group on Breast Cancer Research, Spain
h Hospital Universitari Clinic de Barcelona, Institut Clinic de Malalties Hemato-Oncològiques-ICHMO, Barcelona, Spain
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breast cancerAbstract Background: The PEARL study showed that palbociclib plus endocrine therapy
(palbociclib/ET) was not superior to capecitabine in improving progression-free survival in
postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors, but
was better tolerated. This analysis compared patient-reported outcomes.
Patients and methods: The PEARL quality of life (QoL) population comprised 537 patients,
268 randomised to palbociclib/ET (exemestane or fulvestrant) and 269 to capecitabine. Pa-
tients completed the European Organisation for Research and Treatment of Cancer QLQ-
C30 and QLQ-BR23 and EQ-5D-3L questionnaires. Changes from the baseline and time to
deterioration (TTD) were analysed using linear mixed-effect and stratified Cox regression
models, respectively.
Results: Questionnaire completion rate was high and similar between treatment arms. Signif-
icant differences were observed in the mean change in global health status (GHS)/QoL scores
from the baseline to cycle 3 (2.9 for palbociclib/ET vs. 2.1 for capecitabine (95% confidence
interval [CI], 1.4e8.6; P Z 0.007). The median TTD in GHS/QoL was 8.3 months for palbo-
ciclib/ET versus 5.3 months for capecitabine (adjusted hazard ratio, 0.70; 95% CI, 0.55e0.89;
P Z 0.003). Similar improvements for palbociclib/ET were also seen for other scales as phys-
ical, role, cognitive, social functioning, fatigue, nausea/vomiting and appetite loss. No differ-
ences were observed between the treatment arms in change from the baseline in any item of the
EQ-5D-L3 questionnaire as per the overall index score and visual analogue scale.
Conclusion: Patients receiving palbociclib/ET experienced a significant delay in deterioration
of GHS/QoL and several functional and symptom scales compared with capecitabine,
providing additional evidence that palbociclib/ET is better tolerated.
Trial registration number: NCT02028507 (ClinTrials.gov).
EudraCT study number: 2013-003170-27.
ª 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Palbociclib, an orally bioavailable selective inhibitor of
cyclin-dependent kinases 4 and 6 (CDK4/6) [1], was
approved for the treatment of hormone receptorepositive
human epidermal growth factor receptor 2 (HER2)e
negative metastatic/advanced breast cancer (MBC) as first
or subsequent lines of therapy in combination with endo-
crine therapy (ET), based on the PALOMA-2 and
PALOMA-3 trials. Both, PALOMA-2 including post-
menopausal women and PALOMA-3 with women
regardless of menopausal status, showed that palbociclibplus ET significantly improved progression-free survival
(PFS) versus ET alone [2e4]. In PALOMA-3, patient-re-
ported outcome (PRO) measures indicated that the addi-
tion of palbociclib to fulvestrant resulted in a significant
improvement of overall global quality of life (QoL) and a
significant delay in QoL deterioration [5]. In that study,
menopausal status was a stratification factor, most pa-
tients were postmenopausal and no specific analysis was
performed on QoL changes as per the menopausal status
of the patient [3,5]. In PALOMA-2, palbociclib plus
letrozole maintained QoL and significantly prolonged
these effects in respondents [6]. Indeed, QoL changes
Table 1
Item numbers and definition of the minimally important difference
(MID) as change from the baseline (CFB) values by scales in the
EORTC QLQ-C30 and QLQ-BR23 instruments.
Instruments, scales Item number MIDa
EORTC QLQ-C30
Functional scales
Physical functioning 1e5 6
Role functioning 6e7 8
Emotional functioning 21e24 4
Cognitive functioning 20, 25 2
Social functioning 26e27 7
Quality of life
Global health status/QoL 29e30 10
Symptom scales
Fatigue 10, 12, 18 6
Nausea and vomiting 14e15 6
Pain 9, 19 4
Dyspnoea 8 6
Insomnia 11 3
Appetite loss 13 3
Constipation 16 6
Diarrhoea 17 6
Financial difficulties 28 3
EORTC QLQ-BR-23
Functional scales
Body image 9e12 5
Sexual functioning 14,15 5
Sexual enjoyment 16 5
Future perspective 13 5
Symptom scales
Systemic therapy side-effects 1e4, 6, 7, 8 5
Breast symptoms 20e23 5
Arm symptoms 17,18,19 5
Upset by hair loss 5 5
EORTC QLQ-BR-23, European Organisation for Research and
Treatment of Cancer breast-specific questionnaire; EORTC QLQ-C30,
European Organisation for Research and Treatment of Cancer core
questionnaire; GHS/QoL, global health status/quality of life; (Cocks K
et al. Eur J Cancer 2012; 48:1713e1721 and Osoba D et al. J Clin
Oncol 1998; 16: 139e144).
a A deterioration event is an increase of  the MID from the baseline
for the symptom scales and a decrease of  the MID from the baseline
for the functional scales and GHS/QoL.
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and toxicities of the therapy [7,8]. Chemotherapy is
generally considered as a treatment modality with more
side-effects, hence more severe worsening of QoL than ET
[9]. Various clusters of chemotherapy-related symptoms
differentially influence functioning, which is why the
impact of chemotherapy regimens onglobalQoL is not the
same [8]. The ESMOGuideline and the ESMOMagnitude
of Clinical Benefit Scale tool point to the importance of the
impact of treatment on QoL in addition to efficacy and
safety when deciding on therapies for patients with
MBC [10,11].
PEARL is a phase III trial that compares palbociclib
plus ET (palbociclib/ET) versus capecitabine in post-
menopausal patients with MBC who progressed on an
aromatase inhibitor. In the PEARL, although PFS was
similar in the two arms, treatment with palbociclib/ET
was better tolerated [12]; here, we report the findings on
health-related QoL (HRQoL) based on PROs.
2. Patients and methods
PEARL is a multicentre, international, open-label,
controlled and randomised phase III study with two
treatment arms. Patients were randomised 1:1 to receive
capecitabine versus palbociclib/ET; ET varied as per two
consecutive cohorts of similar characteristics (exemes-
tane in cohort 1 and fulvestrant in cohort 2). Treatment
continued until objective disease progression in accor-
dance with the Response Evaluation Criteria in Solid
Tumours, version 1.1 [13], symptomatic deterioration,
unacceptable toxicity, death or withdrawal of consent,
whichever occurred first. The detailed study design and
characteristics of patients have been previously reported
[12]. The comparison of HRQoL between treatment
arms was a preplanned secondary objective.
The study protocol was approved by every site’s
institutional review board and every national regulatory
agency. All the patients gave written informed consent.
2.1. PRO assessments
PRO measures of HRQoL were assessed using the Eu-
ropean Organisation for Research and Treatment of
Cancer core quality-of-life (EORTC QLQ-C30; v3.0)
instrument [14], its breast cancerespecific module
(EORTC QLQ-BR23; v1.0) [15] and the EQ-5D-3L [16]
questionnaires. Patients were asked to complete each
questionnaire at the baseline, every two cycles for the
first 7 cycles, then every three cycles till the end of
treatment and at the post-treatment visit. The ques-
tionnaires were completed by patients at the clinic
before any study visit procedure.
The EORTC QLQ-C30 is a 30-item questionnaire
composed of a global health status (GHS)/QoL,functional and symptom scales, and the EORTC QLQ-
BR23 is a 23-item companion module consisting of
functional and symptom scales (Table 1). Responses to
all item measures were converted into linear scales
ranging from 0 to 100 using a standard scoring algo-
rithm [17]. For the GHS/QoL and functional scales, a
higher score represents a better level of QoL/func-
tioning. For symptomatic scales, a higher numerical
score represents greater symptom severity.
The EQ-5D-3L is a standardised measure of health
status that comprises a 5-item descriptive health state
classifier and a single-item visual analogue scale (EQ-
VAS) for self-rated health [16,18]. The EQ-5D-3L re-
sponses were linked to country-specific values published
to derive a single summary index score based on the
preferences of Spain [19].
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PRO analyses were performed in cases with baseline and
at least one post-baseline assessment. Completion rates
were summarised by visit in the intention-to-treat pop-
ulation; a questionnaire was considered received if at
least one question was answered. For partially
completed multi-item scales, missing scores were equal
to the average of the completed items if at least half of
the items of that scale were answered but were not
included in the analysis if less than that were completed.
Descriptive statistics, including 95% confidence in-
terval (CI) for the means of actual values, and change
from the baseline (CFB) were tabulated at the scheduled
time points for each scale of the EORTC QLQ-C30 and
EORTC QLQ-BR23 questionnaires as well as for the
EQ-5D-3L index and VAS scores.
The means and 95% CIs of CFB, as well as the
comparisons between treatment arms with their respec-
tive P-values, were analysed using a linear mixed model,
with treatment arms, time points, treatment-time inter-
action terms and stratification criteria as factors and
baseline scores as covariates. A random intercepteonly
model with a first-order autoregressive covariance
structure was used. Baseline scores were compared be-
tween treatment arms using a t-test.
Time to deterioration (TTD), investigated in the
entire study population and in subgroups as per
therapy response, was defined as the time from the
date of randomisation to the date of first increase the
minimally important difference (MID) from the
baseline for the symptom scales or a decrease the
MID from the baseline for the GHS and functional
scales, using an MID from 2 to 10 points [20,21]
(Table 1). Patients with no definitive deterioration
event were censored at their last available QoL
assessment. In patients with no post-baseline assess-
ment, TTD was censored on day 1.
The Kaplan-Meier method was used to estimate the
distribution of TTD for each treatment arm and in
accordance with therapy response. A log-rank test was
performed to compare the TTD between treatment arms.
Adjusted hazard ratios (aHRs) and 2-sided 95% CIs were
estimated using a stratified Cox regression model for the
comparison of palbociclib/ET versus capecitabine.4. Results
4.1. Patients
FromMarch 2014 to July 2018, 601 patients were included
at 37 sites in Spain, Austria, Hungary and Israel. The QoL
population comprised 537 patients (89.3%), 268 of them
included in the palbociclib/ET arm and 269 in the capeci-
tabine arm.Nevertheless, 34 patients in the palbociclib/ET
armand30 in the capecitabine armdidnotmeet the criteriafor being included in the QoL population. Baseline de-
mographic and disease characteristics were well balanced
between arms, except the number of involved sites which
was greater in the capecitabine arm (Table S1).
4.2. Completion rates
The questionnaire completion rate was >82% until cycle
13 (Table S2). All PRO analyses were based on data of
the 14th January 2019 cut-off date at a median follow-
up time of 19.0 months.
4.3. EORTC QLQ-C30 and QLQ-BR23 scores
Baseline mean scores were similar in all dimensions
among the treatment arms, with aGHS/QoL score of 62.1
(95% CI, 59.5e64.6) versus 59.7 (95% CI, 56.9e62.6) for
palbociclib/ET and capecitabine (Table S3).
4.3.1. CFB as per treatment arm
Statistically significant increases in the mean CFB of the
GHS/QoL scores were found in the palbociclib/ET arm
at cycle 16 (5.7 [95% CI, 0.8e10.6]; P Z 0.023) and the
capecitabine arm at cycle 7 (4.1 [95% CI, 0.8e7.3];
P Z 0.014); these improvements were generally main-
tained up to cycle 22 with a decrease at the post-
treatment visits in both arms (Table 2).
Clinically meaningful improvements (MID
point increase from the baseline for functional scales and
MIDdecrease for symptoms scales)wereobserved inboth
study arms at different time points for insomnia, pain and
emotional functioning; while in the palbociclib/ET arm,
such improvements evolved for cognitive functioning and
financial difficulties, in the capecitabine arm, they evolved
for appetite loss and upset by hair loss (Fig. S1).
4.3.2. Comparison of CFB between treatment arms
The overall CFB for all scales of the QLQ-C30 and
QLQ-BR23 is presented in Fig. 1. Significant differences
are observed for diarrhoea favouring palbociclib/ET
(3.7 vs. 6.7; P Z 0.0318) and for constipation (3.9 vs.
1.5; P Z 0.0051) or upset by hair loss (8.3 vs. 2.0;
P Z 0.0076) favouring capecitabine.
As per the linear mixed model analysis, the change of
the GHS/QoL score from the baseline to cycle 3 was 2.9
(95% CI, 0.2e5.6) for palbociclib/ET versus 2.1 (95%
CI, 4.8 to 0.7) for capecitabine, with a mean difference
of 5.0 (95% CI, 1.4e8.6; P Z 0.007) (Table S4). No
significant differences were observed between treatment
arms at other time points (Fig. 2).
With regard to the various dimensions of theQLQ-C30
and QLQ-BR23 tools, there were statistically significant
differences in CFB favouring palbociclib/ET in certain
time points for physical, role and social functioning as
well as body image and symptoms such as fatigue, nausea/
vomiting and diarrhoea. On the other hand, statistically
significant differences in CFB favouring capecitabine
Table 2
Baseline and on-treatment GHS/QoL scores in the EORTC QLQ-C30 scale by treatment arm.
Study visit Palbociclib plus ET n Z 268 Capecitabine n Z 269
Mean (95% CI) Mean CFB (95% CI) P-value Mean (95% CI) Mean CFB (95% CI) P-value
Baseline 62.1 (59.5; 64.7) e e 59.8 (57.1; 62.4) e e
Cycle 3 64.2 (61.5; 67.0) 2.1 (0.8; 5.0) 0.148 58.3 (55.6; 61.1) 1.4 (4.3; 1.4) 0.326
Cycle 5 65.1 (62.1; 68.1) 3.0 (0.1; 6.1) 0.056 61.2 (58.2; 64.2) 1.5 (1.6; 4.5) 0.355
Cycle 7 62.9 (59.6; 66.1) 0.8 (2.6; 4.1) 0.657 63.9 (60.7; 67.0) 4.1 (0.8; 7.3) 0.014
Cycle 10 62.7 (59.0; 66.3) 0.6 (3.2; 4.3) 0.771 63.5 (60.0; 67.1) 3.8 (0.2; 7.4) 0.041
Cycle 13 65.2 (61.2; 69.2) 3.1 (1.0; 7.2) 0.135 63.9 (60.1; 67.7) 4.1 (0.3; 8.0) 0.036
Cycle 16 67.8 (63.0; 72.7) 5.7 (0.8; 10.6) 0.023 63.1 (58.9; 67.3) 3.3 (1.0; 7.6) 0.129
Cycle 19 68.6 (63.3; 73.8) 6.5 (1.2; 11.8) 0.017 61.6 (57.0; 66.2) 1.9 (2.8; 6.5) 0.431
Cycle 22 67.6 (61.6; 73.6) 5.5 (0.6; 11.6) 0.076 65.2 (60.2; 70.3) 5.5 (0.4; 10.6) 0.036
Post-treatment 56.6 (53.6; 59.7) 5.5 (8.6; 2.3) 0.001 56.7 (53.6; 59.7) 3.1 (6.3; 0.0) 0.053
Bold indicates the statistically significant P-values.
The baseline is defined as the last observed measurement on or before the date of the first dose of the study drug. The positive values indicate
improvement, whereas the negative values mean deterioration in global health status.
The linear mixed model was used without covariates to compare scores between visits and the baseline.
CI, confidence interval; CFB, change from the baseline; EORTC QLQ-BR-23, European Organisation for Research and Treatment of Cancer
breast-specific questionnaire; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core questionnaire; ET, endocrine
therapy; GHS/QoL, global health status/quality of life.
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functioning, systemic therapy side-effects, arm
symptoms and upset by hair loss (Table S4).
4.3.3. Time to deterioration
Median TTD was superior in most dimensions of the
QLQ-C30 and QLQ-BR23 instruments in the palboci-
clib/ET arm compared with the capecitabine arm.
Notably, the median TTD in GHS/QoL, using an
MID Z 10, was 8.3 months in patients treated with
palbociclib/ET versus 5.3 months with capecitabine
(aHR, 0.70; 95% CI, 0.55e0.89; P Z 0.003) (Fig. 3A).
The stratified analysis by therapy response showed that
TTD by means of GHS/QoL scores was significantly
worse in patients treated with capecitabine whether they
were non-responders (aHR, 1.7; 95% CI, 1.1e2.5) or
responders (aHR, 1.6; 95% CI, 1.1e2.5) than that of
responder patients treated with palbociclib/ET. No sig-
nificant difference was seen in that respect among non-
responders versus responders in the palbociclib/ET
arm (aHR, 1.2; 95% CI, 0.8e1.9) (Fig. 3B).
Similar improvement was seen in the palbociclib/ET
arm for some other QLQ-C30 scales (physical, role,
cognitive and social functioning and fatigue, nausea/
vomiting, pain, appetite loss and diarrhoea) and for
systemic therapy side-effects in the QLQ-BR23 scale
(Fig. 4A). The HRQoL comparison between the study
arms in responder and non-responder patients indicated
that among non-responders, the risk of deterioration
was lower in most dimensions in the palbociclib/ET arm
(Fig. 4B and C).
4.4. EQ-5D-3L
The summary of EQ-5D-3L levels by visit in each
treatment arm for all dimensions recorded in thisquestionnaire is shown in Fig. S2. The proportions of
patients reporting ‘no problems’ or ‘some problems’ for
any dimension at the baseline were similar between
treatment arms except for pain/discomfort (worse for
capecitabine) (Table 3).
Baseline EQ-5D-3L index scores were similar between
the palbociclib/ET and the capecitabine arms. No sta-
tistically significant differences were observed in the EQ-
5D-3L index scores on treatment between the palbociclib/
ET (0.72 [95% CI, 0.69e0.74]) and the capecitabine arms
(0.71 [95% CI, 0.69e0.73]), P Z 0.672 (Table 3).
CFB in the EQ-5D-3L index score per time point is
shown in Fig. S3. The mean CFB to cycle 3 was 0.03 for
palbociclib plus ET versus 0.01 for capecitabine,
resulting in a mean difference of 0.03 (95% CI,
0.00e0.07; P Z 0.029) (Table S5). No significant dif-
ferences were found at any other time point.
Baseline mean EQ-5D-3L VAS scores were also very
similar between the two study arms, and no statistically
significant difference during treatment was observed
between the palbociclib/ET (67.1 [95% CI, 65.3e69.0])
and capecitabine arms (66.6 [95% CI, 64.9e68.2])
(P Z 0.642). The mean EQ-5D-3L VAS scores were
minimally increased during the study period with no
statistically significant differences from the baseline and
worsened in both treatment arms at the post-treatment
visit (Table 3).5. Discussion
The impact of CDK4/6 inhibitors on treatment out-
comes justifies its use as first-line therapy in hormone
receptorepositive HER2-negative MBC. Although
guidelines and evidence stress the use of modern ET in
this setting before chemotherapy [22e24], analyses of






































































Fig. 1. Overall change from the baseline in EORTC QLQ-C30 and BR23 scales. Changes from the baseline were determined using a
repeated-measures mixed-effect model. A, analysis of change from the baseline for GHS/QoL and functional scales; B, analysis of change
from the baseline for symptom scales. )Statistically significant difference in change from baseline scores between treatment arms. EORTC
QLQ-BR-23, European Organisation for Research and Treatment of Cancer breast-specific questionnaire; EORTC QLQ-C30, European
Organisation for Research and Treatment of Cancer core questionnaire; GHS/QoL, global health status/quality of life.
Z. Kahan et al. / European Journal of Cancer 156 (2021) 70e82 75a mainstay of anticancer therapy and is used as first-line
therapy in about half of the cases [25e27]. Our results
indicating that several components of HRQoL are
significantly superior on palbociclib/ET than on cape-
citabine will contribute to the appropriate positioning ofCDK4/6 inhibitors in the treatment armamentarium.
Notably, the huge cost of adding CDK 4/6 inhibitors to
ET may prevent its general use on the basis of improved
QoL especially in low-income settings; in that situation,
capecitabine could remain an option [28].
Fig. 2. Change from baseline values in the GHS/QoL EORTC QLQ-C30 by treatment arm. The baseline is defined as the last observed
measurement on or before the date of the first dose of the study drug. The time profile provides the average estimates for the CFB for the
interval from the baseline up to the respective cycle as assessed using a linear mixed model with treatment arms, time points, treatment-
time interaction terms and stratification criteria as factors and baseline scores as covariates. Increases from the baseline mean
improvement in GHS/QoL. C, cycle; CFB, change from the baseline; GHS/QoL, global health status/quality of life; CI, confidence in-
terval; D, day; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core questionnaire; ET, endocrine
therapy; PAL, palbociclib; Post-T, post-treatment visit.
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maintained in both treatment arms, specific advantages
occurred on palbociclib/ET: early significant improve-
ment was detected at cycle 3; TTD of self-reported
GHS/QoL was extended by 29% (absolute 2.4 months).
The PRO results reflected the side-effects of the specific
treatment as determinants of different symptoms and
functioning related to QoL. The lack of difference in
EQ-5D-3L scores between the treatment arms could be
due to, first, the generic nature of the tool as compared
with the EORTC questionnaires and, second, to being
less sensitive to changes in health status than other EQ-
5D measures [29]. PEARL was the first randomised
phase III study comparing the outcome (including QoL
aspects) between modern ET with palbociclib versus
capecitabine. Because PFS and overall response rate
(ORR) were not different between the treatment arms
[12], the QoL dimensions were primarily dependent on
the tolerability of treatments. Most importantly, GHS/
QoL showed a significant early improvement, and its
deterioration and that of the specific functioning and
symptom dimensions were significantly delayed in the
palbociclib/ET arm; only sexual enjoyment and upset by
hair loss, typical symptoms of hormone depletion, were
worse in the investigational arm. The PRO analysis in
our study helped to understand the patients’ subjective
appreciation of the compared treatment modalities and
the impact these had on their HRQoL.The recently reported Young-Pearl phase II study
compared the treatment of premenopausal patients with
palbociclib/ET (exemestane with leuprolide) versus
capecitabine [30,31]. The PRO results were similar to
ours: GHS/QoL was maintained in both arms, but some
functioning dimensions and symptoms changed over
time in accordance with treatment. While physical
functioning improved from the baseline in the capeci-
tabine arm the most, role and cognitive functioning
improved in the other arm. The deterioration of symp-
toms such as nausea, diarrhoea and physical functioning
was delayed by palbociclib/ET [31].
The QoL analyses of the PALOMA-2 and PALOMA-
3 trials consistently demonstrated that the addition of
palbociclib to standard first- and second-line ET did not
compromise but enhanced the maintenance of QoL of
postmenopausal patients [5,6]. Furthermore, because of
greater therapeutic activity and longer disease control,
deterioration in various dimensions was delayed; pain, a
typical symptom related to advanced disease, decreased
more and deteriorated later in both studies under pal-
bociclib/ET. Similar to the findings in PALOMA-2, the
deterioration of GHS/QoL was significantly delayed in
patients having partial or complete response on palbo-
ciclib/ET versus patients treated with capecitabine irre-
spective of their therapeutic response [6].
Capecitabine is an oral antimetabolite agent regis-
tered as monotherapy for the treatment of patients with
269 94 37 18 8 6
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Fig. 3. Kaplan-Meier estimates for time to deterioration in GHS/QoL based on the EORTC QLQ-C30 questionnaire data. The adjusted
hazard ratio was obtained using a stratified Cox proportional hazards model with treatment arm, the stratification factors (visceral,
sensitivity to prior ET, prior chemotherapy for MBC) and number of involved sites as covariates. A, analysis in accordance with treatment
arm; B, analysis in accordance with treatment arm and therapeutic response (responders showed partial or complete response, non-
responders did not). aHR, adjusted hazard ratio; MBC, metastatic breast cancer; CI, confidence interval; EORTC QLQ-C30, Euro-
pean Organisation for Research and Treatment of Cancer core questionnaire; ET, endocrine therapy; GHS/QoL, global health status/
quality of life; NA, not applicable; N-R, non-responder; PAL, palbociclib; R, responder; TTD, time to deterioration.
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apy with taxanes and anthracyclines or if these cannot
be given [32]. Its toxicity profile is different from other
cytotoxic agents, with the most side-effects being hand-
foot syndrome, diarrhoea, fatigue, stomatitis and vom-
iting. A very attractive feature is that toxicity may be
well controlled with dose-adjustment/delay while its ef-
ficacy is still being maintained [33]. Because of itsfavourable tolerability, the length of administration
need not be different from that of ET. Most patients
accept oral cancer therapies better than intravenous
(i.v.) ones [7]. We believe that capecitabine is a unique
chemotherapy option with good therapeutic activity and
special impact on QoL. However, in recent literature
reviews and network meta-analyses, the activity of some









Fig. 4. Forest plot: time to deterioration in the various scales of the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires. Adjusted
hazard ratios were obtained using a stratified Cox proportional hazards model with treatment arm, the stratification factors (visceral,
sensitivity to prior ET, prior CT for MBC) and number of involved sites as covariates. A, analysis of all QoL population by treatment
arm. B, analysis of responder patients by treatment arm (the responder had partial or complete response). C, analysis of non-responder
patients by treatment arm (in non-responders, partial or complete response was absent). MBC, metastatic breast cancer; CI, confidence
interval; EORTC QLQ-BR-23, European Organisation for Research and Treatment of Cancer breast-specific questionnaire; EORTC
QLQ-C30, European Organisation for Research and Treatment of Cancer core questionnaire; ET, endocrine therapy; GHS/QoL, global
health status/quality of life; PAL, palbociclib.







EQ-5D-3L severity levels at the baseline and index and VAS scores at the baseline, during treatment and at the post-treatment visit by treatment
arm.






















Mobility 264 177 (67.0) 86 (32.6) 1 (0.4) 266 177 (66.6) 86 (32.3) 3 (1.1) 0.6236
Self-care 263 225 (85.6) 34 (12.9) 4 (1.5) 267 231 (86.5) 34 (12.7) 2 (0.8) 0.4474
Usual activities 263 156 (59.3) 94 (35.7) 13 (5.0) 267 146 (54.7) 110 (41.2) 11 (4.1) 0.6486
Pain/discomfort 267 90 (33.7) 164 (61.4) 13 (4.9) 267 98 (36.7) 142 (53.2) 27 (10.1) 0.0214
Anxiety/depression 265 118 (44.5) 130 (49.1) 17 (6.4) 267 103 (38.6) 148 (55.4) 16 (6.0) 0.8399
EQ-5D-3L index scores n Mean SD 95% CI n Mean SD 95% CI P-valuec
Baseline 262 0.70 0.20 0.68e0.73 266 0.69 0.22 0.66e0.72 0.424
During treatmenta NA 0.72 NA 0.69e0.74 NA 0.71 NA 0.69e0.73 0.672
Post-treatment 166 0.63 0.25 0.59e0.67 179 0.65 0.23 0.61e0.68 0.437
EQ-5D-3L VAS scores n Mean SD 95% CI n Mean SD 95% CI P-valuec
Baseline 263 67.4 18.4 65.2e69.6 265 66.8 19.2 64.5e69.2 0.730
During treatmenta NA 67.1 NA 65.3e69.0 NA 66.6 NA 64.9e68.2 0.642
Post-treatment 170 59.4 20.6 56.3e62.5 179 61.9 19.1 59.1e64.7 0.245
Higher EQ-5D index and VAS scores indicate better health status/QoL. The baseline is defined as the last observed measurement on or before the
date of the first dose of the study drug.
CI, confidence interval; ET, endocrine therapy; SD, standard deviation; VAS, visual analogue scale. Bold source highlighted statistical significance.
a Estimated with a linear mixed model with treatment arms, time points, treatment-time interaction terms and stratification criteria as
factors and baseline scores as covariates.
b Comparison between ‘no problems’ plus ‘some problems’ versus ‘extreme problems’.
c Comparison between treatments arms.
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ET [23,24]. Obviously, the toxicity of these i.v. chemo-
therapy regimens being different probably would affect
QoL dimensions in other ways and to a greater extent by
impairing different symptom clusters than capecitabine
[8]. Therefore, our findings regarding capecitabine’s
impact on QoL should not be generalised to other
chemotherapy regimens.
PRO results may depend on the patient’s country of
origin and ethnicity. Chemotherapy and ET exerted
slightly different effects on HRQoL and daily activity in
patients from Europe versus the United States of
America [9]. Our study population came from countries
with similar values and lifestyles, and the country of
origin was a stratification factor; nevertheless, the pa-
tient population of the Young-Pearl study was uniquely
South Korean [31].
In conclusion, patients receiving palbociclib/ET
experienced a significant delay in deterioration of GHS/
QoL; multiple functional and symptom scales were more
favourable as compared with capecitabine. These find-
ings provide additional evidence that palbociclib/ET is
better tolerated than capecitabine.
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